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Abstract
Background: Macrophage migration inhibitory factor (MIF) is not only a cytokine which has a critical role in several
inflammatory conditions but also has endocrine and enzymatic functions. MIF is identified as an intracellular signaling
molecule and is implicated in the process of tumor progression, and also strongly enhances neovascularization.
Overexpression of MIF has been observed in tumors from various organs. MIF is one of the genes induced by hypoxia in an
hypoxia-inducible factor 1 (HIF-1)-dependent manner.
Methods/Principal Findings: The effect of MIF on HIF-1 activity was investigated in human breast cancer MCF-7 and MDA-
MB-231 cells, and osteosarcoma Saos-2 cells. We demonstrate that intracellular overexpression or extracellular
administration of MIF enhances activation of HIF-1 under hypoxic conditions in MCF-7 cells. Mutagenesis analysis of MIF
and knockdown of 53 demonstrates that the activation is not dependent on redox activity of MIF but on wild-type p53. We
also indicate that the MIF receptor CD74 is involved in HIF-1 activation by MIF at least when MIF is administrated
extracellularly.
Conclusion/Significance: MIF regulates HIF-1 activity in a p53-dependent manner. In addition to MIF’s potent effects on the
immune system, MIF is linked to fundamental processes conferring cell proliferation, cell survival, angiogenesis, and tumor
invasiveness. This functional interdependence between MIF and HIF-1a protein stabilization and transactivation activity
provide a molecular mechanism for promotion of tumorigenesis by MIF.
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Introduction
Macrophage migration inhibitory factor (MIF) was originally
described as a T cell–derived lymphokine but is now recognized as
a pluripotent cytokine involved in multiple functions within and
beyond the immune system [1]. In addition to its original ability to
inhibit migration of macrophages, MIF exhibits a broad range of
immunostimulatory and proinflammatory activities [2]. MIF is
also produced by a variety of mesenchymal, parenchymal, and
epithelial cell types, indicating its potential beyond the immune
system. A number of studies have shown that MIF participates in
the regulation of cell proliferation and differentiation and that it
plays a role in the progress of septic shock, chronic inflammation,
tissue damage, and autoimmune disease. Increased MIF mRNA
expression has been reported in metastatic prostate cancer and
ductal breast carcinoma. Following these findings, it became
evident that MIF is involved in the development of lymphoma and
tumor-associated angiogenesis [3,4]. Inflammation is a critical
component of tumor progression [5]. Many cancers arise from
sites of infection, chronic irritation or inflammation. It is now
becoming clear that the tumor microenvironment, which is
strongly influenced by inflammatory cells, plays a major role in
the neoplastic process, fostering proliferation, survival and
migration of cancer cells. MIF represents an important link
between inflammation and cancer [6,7].
In response to hypoxia, dramatic changes in gene expression
occur leading to increased synthesis of proteins such as
erythropoietin (EPO), glucose transporters (GLUT), glycolytic
enzymes, vascular endothelial growth factor (VEGF), and matrix
metalloproteinases, which mediate cellular and tissue adaptation.
The changes in gene expression are controlled by the transcrip-
tional activator hypoxia-inducible factor 1 (HIF-1). HIF-1 was
identified and purified as a nuclear factor that was induced in
hypoxic cells and bound to the cis-acting hypoxia response element
(HRE) located in the 39-flanking region of the human EPO gene,
which encodes erythropoietin [8]. HIF-1 is a heterodimeric
protein that is composed of HIF-1a and HIF-1H subunits. Both
HIF-1 subunits are members of the basic helix-loop-helix-
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factors [8,9].
The regulation of cellular HIF-1 activity occurs at multiple levels
[10,11]. The mechanisms regulating HIF-1a protein levels and
transcriptional activity have been extensively analyzed. Two proline
residues of HIF-1a are subjected to O2-dependent hydroxylation,
which is required for binding of the von Hippel-Lindau tumor-
suppressor protein (VHL), which is the recognition component of a
ubiquitin-protein ligase that targets HIF-1a for rapid proteasomal
degradation in non-hypoxic cells [12]. Under hypoxic conditions,
the hydroxylation of proline-402 and proline-564 of HIF-1a is
inhibited due to substrate (O2) limitation, resulting in HIF-1a
protein stabilization [13]. The transcriptional activity of HIF-1a is
also negatively regulated under normoxic conditions by hydroxyl-
ation of asparagine-803, which prevents interaction of HIF-1a with
the coactivators p300 and CBP, thus blocking transcriptional
activation [14]. The prolyl and asparaginyl hydroxylases utilize O2
and a-ketoglutarate as substrates [13,14]. In contrast, HIF-1b is
constitutively expressed in most cell types. Immunohistochemical
analysis of human tumor biopsies has revealed overexpression of
HIF-1a in various types of cancer [15]. High HIF-1a protein
expression in tumors reflects stabilization of HIF-1a protein due to
the frequent presence of intratumoral hypoxia as well as increased
synthesis of the protein caused by genetic alterations involving
oncogenes (such as HER2/neu) and tumor suppressor genes (such
as p53, PTEN, and VHL) and autocrine growth factor signaling in
cancer cells [16,17]. HIF-1 activity is also induced by the
stimulation of receptor tyrosine kinases or G protein-coupled
receptors in cancer cells. HER2/neu activation increases the rate of
HIF-1a protein synthesis via phosphatidylinositol 3-kinase (PI3K)
and the downstream serine-threonine kinases AKT (protein kinase
B) and mammalian target of rapamycin (mTOR). IGF-1-induced
HIF-1a synthesis is dependent upon both the PI3K and MAP
Kinase (MAPK) pathways.
Both MIF and HIF-1 play critical roles in cancer and
inflammation [18]. Moreover, MIF has been identified as a
hypoxia-induced gene in cancer cells [19,20]. Based on these
findings we investigated the functional relationship between MIF
and HIF-1 in human cancer cells. In this study, we demonstrate
that intracellular overexpression or extracellular administration of
MIF enhances activation of HIF-1 under hypoxic conditions and
that the regulation is not dependent on redox activity of MIF but
on wild-type p53.
Results
MIF induces HIF-1a protein expression under hypoxic
conditions in MCF-7 cells
To investigate the impact of MIF on HIF-1 activity, the effect of
intracellular transient overexpression of human MIF on HIF-1
protein expression was investigated. MCF-7 cells were transiently
transfected with the expression vector pCMV-3xFLAG-hMIF or
its empty vector pCMV-3xFLAG for 8 h. pCMV-3xFLAG-MIF
significantly increased MIF protein expression (Fig. 1A, left panel).
Cells were exposed to 20% or 1% O2 conditions for 4 h and then
harvested for Western blotting analysis using anti-HIF-1a and
HIF-1b antibodies. HIF-1a protein expression was induced by
hypoxic treatment (Fig. 1A, right panel, lane 3) and furthermore
increased by MIF (lane 4). Expression of HIF-1a under 20% O2
conditions was not significantly affected by MIF overexpression.
HIF-1b protein expression was not affected by transient MIF
overexpression under 1% or 20% O2 conditions (Fig. 1A, right
panel). The effect of MIF overexpression on HIF-1a levels was
dose-dependent (Fig. 1B).
We also investigated the effect of MIF using MCF-7 cells that
stably expressed MIF. In two independent MIF-overexpressing
clones (Fig. 1C, left panel), HIF-1a protein expression was induced
more than control cells (lanes 2 and 3) under 5% (lanes 5 and 8)
and 1% (lanes 6 and 9) O2 (Fig. 1C, right panel). HIF-1a
expression was unchanged under 20% O2 regardless of the MIF
expression level. HIF-1b protein expression was not affected by
MIF (data not shown).
Because MIF is a cellular factor released from cells, we next
investigated the impact of recombinant human MIF protein
(rhMIF) on MCF-7 cells. rhMIF increased HIF-1a expression in a
dose-dependent manner under hypoxic conditions whereas HIF-
1b expression was not affected (Fig. 1D). rhMIF treatment also
augmented HIF-1a protein levels in cells treated with iron chelator
DFX which inhibits HIF-1a-hydroxylase activity.
MIF induces HIF-1-dependent gene expression in MCF-7
cells
We investigated whether MIF affected gene expression
downstream of HIF-1 by RT-PCR analysis. MIF was transiently
overexpressed in MCF-7 cells, which were exposed to 20% and
1% O2 for 18 h. As shown in Fig. 2A, VEGF and GLUT1 mRNA
expression was induced by exposure to 1% O2 (1.73 and 1.77 fold,
respectively). The induction of VEGF and GLUT1 mRNA was
enhanced in hypoxic MIF-overexpressing MCF-7 cells (2.65 and
2.15 fold, respectively). Expression of HIF-1a mRNA was not
affected by hypoxic or MIF treatment (Fig. 2A).
To determine whether the increase in VEGF and GLUT1
mRNA levels reflected an increase in HIF-1 transcriptional
activity, MCF-7 cells were transfected with empty vector or
FLAG-tagged MIF expression vector and the HRE-containing
reporter plasmid p2.1. Overexpression of MIF significantly
increased HRE-dependent gene expression significantly even
under normoxic conditions and under hypoxic conditions in a
MIF expression plasmid-dose dependent manner (Fig. 2B).
Exposure of cells to bacterially produced rhMIF in the culture
media also induced HRE-dependent gene expression under
normoxic and hypoxic conditions (Fig. 2C). MIF also induced
dose-dependent transcription of a luciferase reporter gene
containing the intact human VEGF gene promoter encompassing
nucleotides 22274 to +379 relative to the transcription start site
(Fig. 2D). Overexpression of MIF also potentiated HRE-
dependent gene expression induced by DFX (Fig. 2E).
Next, we investigated the impact of MIF on HIF-1a
transcriptional activity. There are two independent transactivation
domains (TADs) present in HIF-1a, which are designated as the
amino-terminal (amino acids 531–575) and carboxyl-terminal
(amino acids 786–826) TADs. A fusion protein consisting of the
GAL4 DNA-binding domain fused to HIF-1a residues 531–826,
which contains both TADs, is expressed at similar levels under
hypoxic and non-hypoxic conditions and thus can be used to
examine the transcriptional activity of HIF-1a independent of its
protein expression [21]. rhMIF treatment increased transactiva-
tion mediated by GAL4-HIF-1a(531–826) in a dose-dependent
manner (Fig. 2F) under both 20% and 1% O2 conditions. Thus,
MIF not only increased HIF-1a protein levels but also the
transcriptional activity of HIF-1a.
MIF and TRX differentially regulate HIF-1 activity in MCF-
7 cells
Because MIF is also an enzyme that exhibits oxidoreductase
activity based on cysteine thiol-mediated mechanism [22–24], we
next explored a possibility that the effect of MIF on HIF-1a is
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redox mutant MIF-C57/60S expression plasmid, which lacks
oxidoreductase activity, was introduced transiently into MCF-7
cells (Fig. 3A, left panel) Cells were exposed to 20% or 1% O2 and
cell lysates were subjected to immunoblot assays. The redox
mutant MIF-C57/60S also increased HIF-1a protein expression
in either transiently (Fig. 3A, right panel) or stably MIF-expressing
cells (data not shown). HIF-1b expression was not affected by
MIF-wt or MIF-C57/60S (Fig. 3A, right panel).
We next examined the effect of TRX, which also has thiol-
reducingactivityandsharesa similarcatalyticcenterwith MIF. The
wild-type TRX (TRX-wt) expression plasmid pCMV-3xFLAG-
TRX-wt or its redox inactive mutant pCMV-3xFLAG-TRX-C32/
35Swasintroduced transientlyintoMCF-7cells(Fig.3B, leftpanel).
Figure 1. Effect of MIF on HIF-1 protein expression in MCF-7 cells. (A and B) MCF-7 cells were transfected with 2 mg of p3xFLAG-CMV-10
plasmid (EV) or pFLAG-MIF plasmids (A and B lane 4; 2 mg, B lane 3; 0.5 mg). (C) MCF-7 cells were transfected by the plasmids for expression of FLAG
tag (EV) and FLAG-tagged MIF and selected by puromycin resistance. Two clones of MCF-7 cells stably expressing FLAG tag (EV) and FLAG-tagged MIF
(MIF#1 and MIF#2 cells) were established. (D) MCF-7 cells were treated with the indicated doses of bacterially produced recombinant human
(rh)MIF. (E) MCF-7 cells were treated with rhMIF. Cells were exposed to 20% (A, B, C, and D), 5% (C), or 1% (A, B, C, and D) O2 conditions or treated with
100 mM DFX (E) for 4 h. Cell were harvested for immunoblot assay for MIF (A and C), HIF-1a and HIF-1b protein (A, B, C, D, and E). Representative
immunoblots are shown. Intensity of respective bands were analyzed densitometrically and fold induction to respective controls (lane1) are plotted
accordingly as mean6S.D. (n=3) *p,0.05 compared to 20% O2 conditions without MIF (lane 1) (ANOVA).
doi:10.1371/journal.pone.0002215.g001
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expression or hypoxia- or DFX-induced HIF-1a protein levels
(Fig. 3B, right panel). In addition, addition of rhTRX to the culture
media did not affect expression of HIF-1a (data not shown). HIF-1b
expression was not affected by TRX (Fig. 3B, right panel). In
contrast, expression of TRX-wt augmented, whereas TRX-C32/
35S suppressed, hypoxia-induced HRE-dependent gene expression
(Fig. 3C), as reported previously in HeLa cells [25].
Figure 2. Effect of MIF on HIF-1-dependent gene expressions. (A) MCF-7 cells were transfected with the indicated plasmids and exposed to
20% or 1% O2 for 12 h. Then total RNA was isolated. Expression of VEGF, GLUT1, HIF-1a, and 18S rRNA was analyzed by RT-PCR using specific primer
pairs. (B, C, D, and E) MCF-7 cells were transfected with pRL-SV40 encoding Renilla luciferase, FLAG-tagged MIF expression vector (B, C, and E), and
one of the following plasmids encoding firefly luciferase: HRE reporter p2.1 (B, C, and E)o rVEGF promoter reporter pVEGF-KpnI-Luc (D). (F) Constructs
encoding the GAL4 DNA-binding domain (amino acids 1–147) fused to the indicated amino acids of HIF-1a were analyzed for their ability to
transactivate reporter gene GAL4E1bLuc containing five GAL4-binding sites. MCF-7 cells were co-transfected with pRL-SV40 (50 ng), GAL4E1bLuc
(100 ng), GAL4-HIF-1a fusion protein expression plasmids (100 ng), and FLAG-tagged MIF expression vector or empty vector (EV) (200 ng). Cells were
treated with 100 mM of DFX or the indicated dose of rhMIF (F) and exposed to 20% or 1% O2 conditions for 18 h and then harvested. Results shown
represent mean6S.D. of three independent transfections. *; p,0.05 compared to respective controls without MIF treatment (ANOVA).
doi:10.1371/journal.pone.0002215.g002
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HIF-1a protein levels, siRNA for MIF or TRX was introduced
into MCF-7 cells. Protein expression of MIF or TRX was
significantly suppressed by introduction of specific siRNAs (Fig. 4A
and B, left panels). Under 1% O2 conditions, hypoxia-induced
HIF-1a protein expression was inhibited by suppression of MIF
but not that of TRX. In contrast, under 20% O2 conditions,
expression of HIF-1a was not affected by knockdown of either
MIF or TRX (Fig. 4A and B, right panel). Finally, MCF-7 cells
were treated with antioxidants. Vitamin E or N-acetyl cysteine
treatment did not affect HIF-1a or HIF-1b protein expression in
MCF-7 cells under 20% or 1% O2 conditions (Fig. 4C).
The effects of MIF is dependent on CD74 and ERK activity
We examined effect of interfering with the high-affinity binding
protein for MIF CD74 mRNA expression [26]. siRNAs for GFP
Figure 3. Effect of mutation of MIF on HIF-1 activity. (A and B) MCF-7 cells were transfected with 2 mg of p3xFLAG-CMV-10 plasmid, pFLAG-
MIF-wt, or pFLAG-MIF-C57/60S plasmids (A) or p3xFLAG-CMV-10 plasmid, pFLAG-TRX-wt, or pFLAG-TRX-C32/35S plasmids (B). Cell were harvested for
immunoblot assay for MIF (left panel), HIF-1a and HIF-1b protein (right panel). Experiments are repeated for three times. Representative immunoblots
are shown. Intensity of respective bands were analyzed densitometrically and fold induction to lane 1 are plotted accordingly as mean6S.D. *p,0.05
compared to 20% O2 conditions without MIF treatment. (C) MCF-7 cells were transfected with p2.1 reporter plasmid, pRL-SV40 encoding Renilla
luciferase and FLAG-tagged TRX-wt or 2C32/35S expression vector. Cells were exposed to 20% or 1% O2 conditions for 18 h and then harvested. The
luciferase activity of the lysates was determined using the Dual-Luciferase Reporter Assay System (Promega). The ratio of firefly to Renilla luciferase
activity was determined. A normalized mean count6S.D. of three independent transfections is shown as relative luciferase activity (RLA). *; p,0.05
compared to respective control (ANOVA).
doi:10.1371/journal.pone.0002215.g003
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exposed to 1% O2 with or without rhMIF treatment. Knockdown
of CD74 expression abrogated effect of MIF over HIF-1a protein
accumulation under 1% O2 conditions (Fig. 4D).
Because it was reported that MIF induced angiogenesis in a
MAPK-dependent manner [27], we examined involvement of
MAPK in MIF-elicited HIF-1 activation. Treatment with the MEK
inhibitor PD98059 or U0126 suppressed MIF-induced HRE-
dependent gene expression under 1% O2 conditions (Fig. 4E).
The effect of MIF is not dependent on Jab1/CSN5 in MCF-
7 cells
Bae et al. reported that Jab1 (coactivator of c-Jun, also known as
the CSN5 subunit of the COP9 signalosome) interfered with the
binding of HIF-1a to the p53 tumor suppressor protein and thereby
increased HIF-1a protein levels by enhancing HIF-1a stability in
HEK293 cells [28]. Because MIF interacts with Jab1 and negatively
regulates Jab1-controlled pathways [29], we investigated whether
MIF-induced HIF-1 activation is dependent on Jab1. However, we
failed to detect any effect of Jab1/CSN5 on HIF-1a protein
expression (Fig. 5A) and HRE-dependent gene expression (Fig. 5B)
in MCF-7 cells under either 20% or 1% O2 conditions.
The effect of MIF is dependent on p53
MIF was identified as a binding protein and a functional
suppressor of p53 [28,30]. We next explored a possibility that p53
is involved in MIF-induced HIF-1 activation. The effect of rhMIF
on HIF-1a protein expression in MDA-MB-231 cells, which
express mutant p53, and p53-null osteosarcoma Saos-2 cells was
examined (Fig. 6A). In contrast to results with MCF-7 cells
harboring wild-type p53, rhMIF treatment did not increase HIF-
1a protein expression under 20% or 1% O2 in either MDA-MB-
231 or Saos-2 cells (Fig. 6B). Moreover, rhMIF treatment did not
enhance hypoxia-induced HRE-dependent gene expression in
Saos-2 cells (Fig. 6C). In accord with this result, MCF-7 cells
transfected with the vector encoding short-hairpin RNA against
p53 [31] did not respond to rhMIF under hypoxic conditions
(Fig. 6D), although basal HIF-1 activity was unregulated by
knockdown of p53. To investigate involvement of wild-type p53 in
regulation of HIF-1a protein, binding between MIF and p53 in
Figure 4. Effect of MIF-gene silencing on HIF-1 activity. (A, B, and D) MCF-7 cells were transfected with siRNA against MIF, TRX, CD74, or green
fluorescence protein (GFP) as a negative control. Cells were exposed to 20% or 1% O2 conditions and were harvested for immunoblot assay for MIF or
TRX (left panels) or HIF-1a and HIF-1b protein expression (right panels). Representative immunoblots are shown. Intensity of respective bands were
analyzed densitometrically and fold induction to lane 1 are plotted accordingly as mean6S.D. (n=3) (A, B, and C). *p,0.05 compared to 20% O2
conditions without treatment (ANOVA). (C) MCF-7 cells were pre-treated with 10 mM a-tocopherol or 10 mM NAC and then exposed to 20% or 1% O2
conditions for 4 h. Cells were harvested for immunoblot assay for HIF-1a and HIF-1b protein. (D) siRNAs for GFP or CD74 were introduced into MCF-7
cells. The cells were exposed to 1% O2 with or without rhMIF treatment. Cells were harvested for immunoblot assay for MIF HIF-1a protein. (E) MCF-7
cells were transfected with HRE reporter p2.1 and pRL-SV40 encoding Renilla luciferase. Cells were treated with the indicated dose of rhMIF and
exposed to 20% or 1% O2 conditions for 18 h and then harvested. Results shown represent mean6S.D. of three independent transfections. *; p,0.05
compared to respective controls (ANOVA).
doi:10.1371/journal.pone.0002215.g004
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captured p53 was less in MDA-MB-231 cells than MCF-7 cells,
which expresses wild-type p53 (Fig. 6E).
Discussion
In this study, we demonstrate that intracellular overexpression
or extracellular administration of MIF increased HIF-1a protein
expression and HIF-1-dependent gene expressions in MCF-7
breast cancer cells. Knockdown of MIF or CD74 expression by
siRNA suppressed hypoxia-induced HIF-1a activation. In addi-
tion, we demonstrated that the effect of MIF on HIF-1 is observed
only in the presence of wild-type not but mutant p53.
We adopted two protocols of MIF treatment. One is
intracellular overexpression of MIF, and extracellular administra-
tion of bacterially produced rhMIF. Both the treatments enhanced
hypoxia-induced HIF-1 activation. It is proposed that cells take up
extracellular MIF is taken by endocytosis in membrane-bound
vesicles, which interact with intracellular signaling molecules
including Jab1/CSN5 [29] and p53 [32].
MIF interacts with the intracellular signaling intermediate Jab1/
CSN5, which was reported to regulate the stability of HIF-1a protein
[28,29,33]. Overexpression of Jab1 stabilizes HIF-1a protein in
HEK293 and MIA-paca-2 cells and activates HIF-1-dependent
transcription [28,34]. But in MCF-7 cells, forced expression of Jab1
did not increase HIF-1a protein or HRE-dependent gene expression
under either 20% or 1% O2. These results indicate that Jab1/CSN5
does not critically contribute to MIF-induced HIF-1 activation in
MCF-7 cells. The molecular mechanism underlying the difference
between cell lines remains to be established.
Several reports demonstrated that MIF is an oxidoreductase
with insulin disulfide bond reducing activity [22–24]. As shown in
Fig. 4, the redox mutant MIF-C57S/C60S can activate HIF-1.
TRX is also an oxidoreductase that is involved in intracellular
signal transduction [24]. In contrast to previous reports using
MCF-7 cells [35,36], but in accordance with our report using
HeLa cells [25], neither overexpression nor knockdown of TRX
affected HIF-1a protein expression at 20% O2 or 1% O2 in the
present study (Fig. 3C and 4B). Moreover, treatment with
antioxidants did not affect HIF-1a protein expression (Fig. 4C).
Together, we conclude that MIF enhances HIF-1 activity in a
redox activity-independent manner.
The type II transmembrane protein CD74 was identified as a
high-affinity binding protein for MIF [26]. In this study, we
indicated that knockdown of CD74 expression by siRNA made
MCF-7 cells to be insensitive to MIF treatment in expression of
HIF-1a under hypoxia (Fig. 4D). MIF binds to the extracellular
domain of CD74, and CD74 is required for MIF-induced
activation of the extracellular signal–regulated kinase–1/2 MAP
kinase cascade, cell proliferation, and release of arachidonates
such as PGE2 [37,38]. We also showed that MIF-induced HIF-1a
transcriptional activation in MCF-7 cells was blocked by the MEK
inhibitors PD98059 or U0126 (Fig. 4E). The evidence indicates
that CD74-dependent signaling pathway contributes to extracel-
lularly administrated MIF-induced HIF-1 activation (Fig. 7).
MIF is a potent cytokine that overcomes p53 function by
suppressing its transcriptional activity [30,39]. It was reported that
p53 interacts with HIF-1a in vivo and that p53 promotes the
ubiquitin-mediated degradation of HIF-1a [40]. The experimental
results shown as Fig. 6 indicates that effect of MIF on HIF-1 is p53-
Figure 5. Involvement of Jab1 in MIF-induced HIF-1 activation. (A) MCF-7 cells were transfected with pSRa-HA-1 or pSRa-HA-Jab1. Cells were
exposed to 20% or 1% O2 conditions and were harvested for immunoblot assay for Jab1 (left panels) or HIF-1a and HIF-1b protein expression (right
panels). Representative immunoblots are shown. Intensity of respective bands were analyzed densitometrically and fold induction to lane 1 are
plotted accordingly as mean6S.D. *p,0.05 compared to 20% O2 conditions without Jab1 (Student t-test). (B) MCF-7 cells were transfected with p2.1
reporter plasmid, pRL-SV40 encoding Renilla luciferase and pSRa-HA-1 or pSRa-HA-Jab1 expression vector. Cells were exposed to 20% or 1% O2
conditions for 18 h and then harvested. The luciferase activity of the lysates was determined using the Dual-Luciferase Reporter Assay System
(Promega). The ratio of firefly to Renilla luciferase activity was determined. A normalized mean count6S.D. of three independent transfections is
shown as relative luciferase activity (RLA).
doi:10.1371/journal.pone.0002215.g005
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hypoxic conditions by sequestrating p53 from HIF-1a (Fig. 7).
In addition to MIF’s potent effects on the immune system, MIF
is linked to fundamental processes conferring cell proliferation, cell
survival, angiogenesis, and tumor invasiveness. A line of studies
report the increased expression of MIF in solid tumors. Several
studies also indicate that MIF expression closely correlates with
tumor aggressiveness and metastatic potential, suggesting as
important contribution to cancer malignancy by MIF [41]. The
link of MIF to HIF-1a protein stabilization and transactivation
activity provides molecular mechanism for MIF-dependent
promotion of tumorigenesis.
Materials and Methods
Cell culture and reagents
Human breast carcinoma MCF-7 (wild-type p53), MDA-MB-
231 (mutant p53), and osteosarcoma Saos-2 (p53-null) cell lines
were grown in Dulbecco’s modified essential medium supple-
mented with 10% FBS, 100 units/ml penicillin, and 100 g/ml
streptomycin. N-acetyl-cysteine (NAC), the iron chelator desfer-
rioxamine (DFX), and a-tocopherol were from Sigma-Aldrich (St.
Louis, MO). Recombinant human (rh) MIF was from R&D
systems (Minneapolis, MN). Recombinant human thioredoxin
(TRX) was prepared following a protocol described previously
[42,43].
Plasmids
Human MIF or Jun activation domain-binding protein 1(Jab1)
cDNA was cloned by RT-PCR from a HeLa cell cDNA library,
using specific primers to based on the human MIF or Jab1
sequence, respectively. For expression plasmids with N-terminal
3xFLAG-tagged MIF and TRX, PCR-amplified fragments were
inserted into p3xFLAG-CMV-10 plasmid (Sigma-Aldrich). Muta-
genesis of MIF (C57/60S) was performed using a protocol on
Figure 6. Involvement of p53 in MIF-induced HIF-1 activation. (A and B) MDA-MB-231 cells and Saos-2 cells were exposed to 20% or 1% O2
conditions with or without rhMIF treatment for 4 h and then harvested for immunoblot assay for p53 (A) and HIF-1a and HIF-1b protein (B). (C and D)
MCF-7 cells and Saos-2 cells were transfected with p2.1 reporter and pRL-SV40 (C). MCF-7 cells transfected with pSUPER (EV) or pSUPER-p53(p53)
were transfected with p2.1 reporter and pRL-SV40 (D). Cells were exposed to 20% and 1% O2 conditions with or without rhMIF treatment and then
harvested for luciferase assay. Fold induction of relative luciferase activity was calculated. A normalized mean value6S.D. of three independent
transfections is shown as fold induction. *; p,0.05 compared to respective control (ANOVA). (E) MCF-7 and MDA-MB-231 cells transfected with
pFLAG-MIF-wt plasmid were exposed to 1% O2 and then cells were harvested. 500 mg of lysates were incubated with anti-FLAG affinity agarose beads
and captured protein was eluted and analyzed by Western blot with anti-p53 antibody. 50 mg of lysate were analyzed by Western blot with anti-p53
antibody.
doi:10.1371/journal.pone.0002215.g006
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previously [43]. To establish stable transfectants, 3xFLAG-tagged
expression cassettes of MIF and TRX were amplified by PCR and
transferred to the expression vector pQCXIP (Clonthech, Palo
Alto, CA). For the influenza hemagglutin (HA) epitope-tagged
Jab1 expression plasmid pSRa-HA-Jab1, PCR-amplified cDNA of
Jab1 was inserted into pSRa-HA1 [45]. A vector encoding short-
hairpin RNA against p53 (pSUPER-p53) was kindly provided by
Dr. Agami, the Netherlands Cancer Institute [31].
Hypoxic treatment
Tissue culture dishes were transferred to a modular incubator
chamber (Billups-Rothenberg, Del Mar, CA) which was flushed
with 1% O2-5% CO2-94% N2, sealed, and placed at 37uC
[46,47].
Immunoblot assays
Whole cell lysates were prepared using ice-cold lysis buffer
[0.1% SDS, 1% NP40, 5 mM EDTA, 150 mM NaCl, 50 mM
Tris-Cl (pH 8.0)] supplemented with7 2 mM dithiothreitol, 1 mM
NaVO3, and Complete protease inhibitor
TM (Roche Diagnostics,
Basel, Switzerland). Samples were centrifuged at 10,0006 g to
pellet cell debris. For HIF-1a and HIF-1b, 100-mg aliquots were
fractionated by SDS-polyacrylamide gel electrophoresis (SDS-
PAGE) and subjected to immunoblot assay using mouse
monoclonal antibodies against HIF-1a (BD Biosciences, San Jose,
CA), or HIF-1b (BD Biosciences) at 1:1000 dilution and HRP-
conjugated sheep antibody against mouse IgG (GE Healthcare
Bio-Science Corp., Piscataway, NJ.) at 1:2000 dilution [46]. For
MIF, TRX, Jab1, and p53, 20-mg aliquots were analyzed by SDS-
PAGE and subjected to immunoblot assay using rabbit polyclonal
antibodies against MIF (FL-115, Santa Cruz Biotechnology, Inc.,
Santa Cruz, CA), TRX (FL-105, Santa Cruz Biotechnology, Inc),
Jab1 (FL-334, Santa Cruz Biotechnology, Inc.), and p53 (DO-1,
Santa Cruz Biotechnology, Inc) at 1:1000 dilution and HRP-
conjugated goat antibody against rabbit IgG (GE Healthcare Bio-
Science Corp.) at 1:2000 dilution. Chemiluminescent signal was
developed using ECL reagent (GE Healthcare Bio-Science Corp.).
Reverse Transcription (RT)-PCR
The RT-PCR protocol was described previously [46,47]. After
treatment, cells were harvested and RNA was isolated with
Figure 7. Involvement of MIF in HIF-1 regulation in MCF-7 cells. HIF-1a protein stabilization and transactivation activity induced by MIF is
dependent on p53- and MAPK-dependent signaling pathway.
doi:10.1371/journal.pone.0002215.g007
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TM (Invitrogen). 1 mg of total RNA was subjected to first
strand cDNA synthesis using random hexamers (SuperScript II
RT kit, Invitrogen). cDNAs were amplified with TaqGold
TM
polymerase (Roche Diagnostics) in a thermal cycler with the
specific primers (sequences provided on request). For each primer
pair, PCR was optimized for cycle number to obtain linearity
between the amount of input RT product and output PCR
product. Thermocycling conditions were 30 s at 94uC, 60 s at
57uC, and 30 s at 72uC for 28 (glucose transporter 1 [GLUT1]),
25 (VEGF and HIF-1a) and 22 (18S) cycles preceded by 10 min at
94uC. PCR products were fractionated by 1% SeaKem GTG
Agarose gel electrophoresis, stained with ethidium bromide, and
visualized with UV.
Reporter Gene Assays
Reporter assays were performed in MCF-7 cells. 5610
4 cells
were plated per well on the day before transfection. Plasmid p2.1
contains a 68-bp HRE from the ENO1 gene inserted upstream of
an SV40 promoter in the luciferase reporter plasmid pGL2-
Promoter (Promega, Madison, WI). Constructs encoding the
GAL4 DNA-binding domain (amino acids 1–147) fused to the
amino acids of HIF-1a (531–826) were analyzed for their ability to
transactivate reporter gene GAL4E1bLuc, which contains 5 copies
of a GAL4 binding site upstream of a TATA sequence and firefly
luciferase coding sequences. The reporter gene plasmid and the
control plasmid pRL-SV40 (Promega), which contains SV40
promoter sequences upstream of Renilla reniformis luciferase coding
sequences, were pre-mixed and used. In each transfection,
indicated dose of test plasmids, 200 ng of reporter gene plasmid,
and 50 ng of the control were pre-mixed with Fugene 6
TM
transfection reagent (Roche Diagnostics). In each assay the total
amount of DNA was held constant by addition of corresponding
empty vectors. After treatment, the cells were harvested and the
luciferase activity was determined using the Dual-Luciferase
Reporter Assay System (Promega). The ratio of firefly to Renilla
luciferase activity was determined. A normalized mean6S.D.
based on three independent transfections is shown as relative
luciferase activity (RLA).
Gene silencing using short interfering RNA (siRNA)
Two oligonucleotides consisting of ribonucleosides except for
the presence of 29-deoxyribonucleosides (dTdT) at the 39 end, 59-
GCCUGCACAGCAUCGGCAAdTdT-39 and 59-UUGCC-
GAUGCUGUGCAGGCdTdT-39 for siRNAMIF and 59-CCAU-
CUGCGUGACAAUAAAdTdT-39 and 59-UUUAUUGU-
CACGCAGAUGGdTdT-39 for siRNATRX, were synthesized
and annealed (Qiagen Inc., Valencia, CA.). siRNAs corresponding
to human CD74 (cat. no. SI00063049) were from Qiagen Inc.
MCF-7 cells were transfected by 100 nM siRNA using HiPer-
Fect
TM Transfection Reagent (Qiagen Inc.) following a protocol
provided by the manufacturer.
Data analysis
All the experiments were done at least three times (unless
mentioned otherwise) and representative blots are shown. Data
were expressed as mean6S.D. Significance tests (ANOVA with
post-hoc test or Student’s t-test) were performed using Prism
TM
version 4 application.
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